In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole

פריטים דומים

• In Vitro Activities of BMS-207147 against Over 600 Contemporary Clinical Bloodstream Isolates of Candida Species from the SENTRY Antimicrobial Surveillance Program in North America and Latin America
  מאת: Diekema, D. J., et al.
  יצא לאור: (1999)
• In Vitro Activities of Ravuconazole (BMS-207147) against 541 Clinical Isolates of Cryptococcus neoformans
  מאת: Yamazumi, T., et al.
  יצא לאור: (2000)
• Activity of a new triazole, Sch 56592, compared with those of four other antifungal agents tested against clinical isolates of Candida spp. and Saccharomyces cerevisiae.
  מאת: Pfaller, M A, et al.
  יצא לאור: (1997)
• In Vitro Activities of the New Antifungal Triazole SCH 56592 against Common and Emerging Yeast Pathogens
  מאת: Barchiesi, Francesco, et al.
  יצא לאור: (2000)
• In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
  מאת: Pfaller, M. A., et al.
  יצא לאור: (2001)